BACKGROUND: Mesothelin is an ideal tumor-associated marker for the development of targeted therapy due to its limited expression in normal tissues. The aim of this study was to evaluate mesothelin expression in triple-negative breast cancer (TNBC) and its correlation with survival outcomes. METHODS: Mesothelin expression was completed by using immunohistochemistry and was quantified by the H score. An H score > 10 was considered positive. Patient characteristics were compared by mesothelin expression. The Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards models was used to adjust for patient and tumor characteristics. RESULTS: The median age was 52 years. Of the 109 patients with TNBC, 37 (34%) were positive for mesothelin expression. There were no differences on patient and/or tumor characteristics by mesothelin expression with the exception of high frequency of lymphovascular space invasion in mesothelin-negative tumors (2P = .03). At a median follow-up of 75.8 months, 20 (18.3%) patients had experienced a recurrence, and 22 (20.2%) had died. Five-year progression-free survival was 87% and 92% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P = .43). Five-year overall survival was 85% and 91% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P = .57), respectively. Mesothelin expression was not an independent predictor of survival outcomes. CONCLUSION: Mesothelin expression was identified in 34% of patients with TNBC. Mesothelin expression did not correlate with survival outcomes in patients with TNBC.
BACKGROUND:Mesothelin is an ideal tumor-associated marker for the development of targeted therapy due to its limited expression in normal tissues. The aim of this study was to evaluate mesothelin expression in triple-negative breast cancer (TNBC) and its correlation with survival outcomes. METHODS:Mesothelin expression was completed by using immunohistochemistry and was quantified by the H score. An H score > 10 was considered positive. Patient characteristics were compared by mesothelin expression. The Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards models was used to adjust for patient and tumor characteristics. RESULTS: The median age was 52 years. Of the 109 patients with TNBC, 37 (34%) were positive for mesothelin expression. There were no differences on patient and/or tumor characteristics by mesothelin expression with the exception of high frequency of lymphovascular space invasion in mesothelin-negative tumors (2P = .03). At a median follow-up of 75.8 months, 20 (18.3%) patients had experienced a recurrence, and 22 (20.2%) had died. Five-year progression-free survival was 87% and 92% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P = .43). Five-year overall survival was 85% and 91% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P = .57), respectively. Mesothelin expression was not an independent predictor of survival outcomes. CONCLUSION:Mesothelin expression was identified in 34% of patients with TNBC. Mesothelin expression did not correlate with survival outcomes in patients with TNBC.
Authors: Sharon L Swierczynski; Anirban Maitra; Susan C Abraham; Christine A Iacobuzio-Donahue; Raheela Ashfaq; John L Cameron; Richard D Schulick; Charles J Yeo; Ayman Rahman; David A Hinkle; Ralph H Hruban; Pedram Argani Journal: Hum Pathol Date: 2004-03 Impact factor: 3.466
Authors: Peter B Illei; Christine Alewine; Marianna Zahurak; Morgan L Cowan; Elizabeth Montgomery; Raffit Hassan; Laiman Xiang; Ira Pastan; Ronan J Kelly Journal: Appl Immunohistochem Mol Morphol Date: 2016-04
Authors: Yun R Li; Rena R Xian; Amy Ziober; Jose Conejo-Garcia; Alfredo Perales-Puchalt; Carl H June; Paul J Zhang; Julia Tchou Journal: Breast Cancer Res Treat Date: 2014-09-06 Impact factor: 4.872
Authors: Gary Tozbikian; Edi Brogi; Kyuichi Kadota; Jeffrey Catalano; Muzaffar Akram; Sujata Patil; Alice Y Ho; Jorge S Reis-Filho; Britta Weigelt; Larry Norton; Prasad S Adusumilli; Hannah Yong Wen Journal: PLoS One Date: 2014-12-15 Impact factor: 3.240
Authors: Raffit Hassan; Christine Alewine; Idrees Mian; Anna Spreafico; Lillian L Siu; Carlos Gomez-Roca; Jean-Pierre Delord; Antoine Italiano; Ulrik Lassen; Jean-Charles Soria; Rastilav Bahleda; Anish Thomas; Seth M Steinberg; Cody J Peer; William D Figg; Gerhard Niederfellner; Valérie Méresse Naegelen; Ira Pastan Journal: Cancer Date: 2020-09-01 Impact factor: 6.921
Authors: Liu Zhenjiang; Martin Rao; Xiaohua Luo; Elisabeth Sandberg; Jiri Bartek; Esther Schoutrop; Anna von Landenberg; Qingda Meng; Davide Valentini; Thomas Poiret; Georges Sinclair; Inti-Harvey Peredo; Ernest Dodoo; Markus Maeurer Journal: EBioMedicine Date: 2017-08-30 Impact factor: 8.143